New hope for pancreatic cancer: experimental combo enters phase 3 trial

NCT ID NCT07562152

First seen May 08, 2026 · Last updated May 08, 2026

Summary

This phase 3 study tests whether adding the experimental drug atebimetinib to a modified chemotherapy regimen helps people with metastatic pancreatic cancer live longer compared to standard chemotherapy alone. About 510 adults who have not had prior treatment for their advanced pancreatic cancer will participate. The study measures overall survival, tumor shrinkage, and disease control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope

    RECRUITING

    Phoenix, Arizona, 85338, United States

    Contact Email: •••••@•••••

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

    Contact

  • City of Hope

    RECRUITING

    Chicago, Illinois, 60099, United States

    Contact

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

    Contact Email: •••••@•••••

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Email: •••••@•••••

  • Taylor Cancer Research Center

    RECRUITING

    Maumee, Ohio, 43537, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.